Journal article
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study
Rachel Sacks-Davis, Jason Grebely, Gregory J Dore, William Osburn, Andrea L Cox, Thomas M Rice, Timothy Spelman, Julie Bruneau, Maria Prins, Arthur Y Kim, Barbara H McGovern, Naglaa H Shoukry, Janke Schinkel, Todd M Allen, Meghan Morris, Behzad Hajarizadeh, Lisa Maher, Andrew R Lloyd, Kimberly Page, Margaret Hellard
JOURNAL OF INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2015
Abstract
BACKGROUND: We aimed to characterize the natural history of hepatitis C virus (HCV) reinfection and spontaneous clearance following reinfection (reclearance), including predictors of HCV reclearance. METHODS: Data were synthesized from the 9 prospective cohorts of the International Collaboration of Incident Human Immunodeficiency Virus and HCV in Injecting Cohorts study, which evaluated HCV infection outcomes among people who inject drugs. Participants with primary HCV infection were classified as having achieved viral suppression if they had negative results of at least 1 subsequent HCV RNA test. Those with positive results of an HCV RNA test following viral suppression were investigated fo..
View full abstractGrants
Awarded by National Institutes of Health (NIH)
Awarded by National Institute on Drug Abuse, NIH
Awarded by National Health and Medical Research Council
Awarded by Canadian Institutes of Health Research
Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
Awarded by NATIONAL INSTITUTE ON DRUG ABUSE
Awarded by Alberta Innovates
Funding Acknowledgements
This work was supported by the National Institutes of Health (NIH; grants U19 AI088791 [to A. L. C.] and U19 AI066345 [to A. Y. K., T. M. A. and B. H. M.]); the National Institute on Drug Abuse, NIH (grants R01 DA031056 [to the InC<SUP>3</SUP> Study], R01 DA033541 [to A. Y. K.], R01 DA016017 [to K. P. and M. M.], and R01 DA15999-01 [to G. J. D., J. G., A. R. L., and M. H.]); the Victorian Operational Infrastructure Support Program (to the Burnet Institute); the National Health and Medical Research Council (postgraduate scholarship to R. S.-D., practitioner research fellowships to G. J. D. and A. R. L., senior research fellowships to M. H. and L. M., career development fellowship to J. G., and project grants 630483 [to the Hepatitis C Virus Incidence and Transmission Study-Community {HITS-c}] and 331312 [to the Networks 2 {N2} project]); Fonds de la Recherche du Quebec-Sante (research career awards to J. B. and N. H. S.); an Australian postgraduate PhD award (to B. H.); the Canadian Institutes of Health Research (grants MOP-103138 and MOP-106468 to J. B. and N. H. S.); the Netherlands National Institute for Public Health and the Environment (to the Amsterdam Cohort Study); the University of New South Wales Hepatitis C Vaccine Initiative (to the HITS-c); the Australian Centre for HIV and Hepatitis Virology Research (to the N2 project); and the Centre for Research Excellence into Injecting Drug Use (to M. H., G. J. D., L. M., J. G., and R. S. D.).